Modulation of Postoperative Scarring with Tacrolimus and Octreotide in Experimental Glaucoma Filtration Surgery

dc.contributor.authorArslan, Sermal
dc.contributor.authorAydemir, Orhan
dc.contributor.authorGuler, Mete
dc.contributor.authorDagli, Adile Ferda
dc.date.accessioned2026-08-12T17:31:31Z
dc.date.issued2012
dc.departmentFırat Üniversitesi
dc.description.abstractPurpose: The purposes of this study were to investigate the effects of topically administrated Tacrolimus and Octreotide on modulation of postoperative scarring in experimental glaucoma filtration surgery and to compare the antifibrotic properties of these agents with mitomycin-C (MMC). Material and methods: A total of 28 New Zealand rabbits weighing 2.5-3 kg were randomly divided into a surgical control (SC) group and three experimental groups. Standard filtration surgeries were performed on the right eyes of all the rabbits. The rabbits in the SC group received only vehicle after the surgeries, whereas the rabbits in the three experimental groups were treated either with 0.4 mg/mL MMC during the surgery (MMC group) or with 0.3 mg/mL Tacrolimus drop four times a day (TT group) or with 10 mu g/mL Octreotide drop three times a day (OT group) for 14 days. The animals were killed on day 14, eyes were enucleated and histologically and immunohistochemically analyzed. Results: In SC group mean fibroblast, mononuclear cell number and fibroblast growth factor-beta (FGF-beta), transforming growth factor-beta (TGF-beta) immunostaining intensity was higher than all treatment groups. In OT group mean fibroblast number was lesser than MMC (p < 0.01) and TT (p < 0.05) group. In TT group mean fibroblast number was lesser than MMC group (p < 0.05). Mean mononuclear cell number was similar between MMC, OT and TT groups (p > 0.05). In MMC, OT and TT groups mean TGF-beta and FGF-beta immunostaining intensity was similar (p > 0.05). Conclusions: Topically administration of Tacrolimus and Octreotide effectively reduced the subconjuntival scarring response 2 weeks after experimental glaucoma filtration surgery.
dc.identifier.doi10.3109/02713683.2011.635404
dc.identifier.endpage233
dc.identifier.issn0271-3683
dc.identifier.issue3
dc.identifier.pmid22335810
dc.identifier.scopus2-s2.0-84857438734
dc.identifier.scopusqualityQ2
dc.identifier.startpage228
dc.identifier.urihttps://doi.org/10.3109/02713683.2011.635404
dc.identifier.urihttps://hdl.handle.net/11508/56295
dc.identifier.volume37
dc.identifier.wosWOS:000300342700009
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherInforma Healthcare
dc.relation.ispartofCurrent Eye Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectGlaucoma
dc.subjectMitomycin-C
dc.subjectoctreotide
dc.subjectTacrolimus
dc.subjectTrabeculectomy
dc.titleModulation of Postoperative Scarring with Tacrolimus and Octreotide in Experimental Glaucoma Filtration Surgery
dc.typeArticle

Dosyalar